DelveInsight’s, “Interstitial Lung Disease Pipeline Insight, 2023,” report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Disease pipeline drug profiles, including Interstitial Lung Disease clinical trials and nonclinical stage products. It also covers the Interstitial Lung Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Interstitial Lung Disease emerging drugs, the Interstitial Lung Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Interstitial Lung Disease pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Interstitial Lung Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Interstitial Lung Disease clinical trials studies, Interstitial Lung Disease NDA approvals (if any), and product development activities comprising the technology, Interstitial Lung Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Interstitial Lung Disease Pipeline Report
To explore more information on the latest breakthroughs in the Interstitial Lung Disease Pipeline treatment landscape of the report, click here @ Interstitial Lung Disease Pipeline Outlook
Interstitial Lung Disease Overview
Interstitial lung disease (diffused parenchymal diseases) are a heterogeneous group of disorders characterized by fibrosis (scarring) of the lungs. These are classified on the basis of histopathological, radiologic and clinical parameters. The classification system used to describe interstitial lung disease categorizes conditions based on clinical, histopathological or radiologic parameters. Clinical classification groups ILD by its causes to help differentiate exogenous or endogenous factors. Interstitial lung disease diseases without identifiable causes get grouped under idiopathic/primary which uses the histopathological and radiological approach as its infrastructure. Many of the subsets of the disease are of unknown etiology.
Latest Developmental Activities in the Interstitial Lung Disease Treatment Landscape
For further information, refer to the detailed Interstitial Lung Disease Unmet Needs, Interstitial Lung Disease Market Drivers, and Interstitial Lung Disease Market Barriers, click here for Interstitial Lung Disease Ongoing Clinical Trial Analysis
Interstitial Lung Disease Emerging Drugs Profile
DWN12088 is an investigational therapy for idiopathic pulmonary fibrosis (IPF), that has shown the promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase I clinical trial that enrolled healthy volunteers. DWN12088 is an investigational IPF therapy that limits the body’s ability to produce collagen by preventing an enzyme called glutamyl-prolyl-tRNA synthetase from adding proline to the protein’s sequence. The FDA designated it as an orphan drug for idiopathic pulmonary fibrosis (IPF) in 2019. The drug is currently in Phase II stage of clinical trial evaluation to treat IPF.
LYT-100 is PureTech’s most advanced wholly-owned therapeutic candidate. A deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, LYT-100 is being advanced for the potential treatment of conditions involving inflammation and fibrosis, including lung disease (e.g., IPF and potentially other PF-ILDs and Long COVID respiratory complications and related sequelae), and disorders of lymphatic flow, such as lymphedema. PureTech completed a Phase 1 multiple ascending dose and food effect study evaluating LYT-100 in healthy volunteers and found it to be well-tolerated at all doses tested. PureTech is evaluating LYT-100 in a Phase 2 trial as a potential treatment for Long COVID respiratory complications and related sequelae as well as in a Phase 2a proof-of-concept study in patients with breast cancer-related, upper limb secondary lymphedema. PureTech is also advancing LYT-100 for the treatment of IPF and potentially other PF-ILDs and is planning registration-enabling studies. PureTech also expects to initiate a Phase 2 dose-ranging trial of LYT-100 in patients with IPF in the first half of 2022.
BMS 986278, a lysophosphatidic acid receptor antagonist (LPA1) is being developed by Bristol-Myers Squibb, the treatment of idiopathic pulmonary fibrosis. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and β-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human lung fibroblasts. Currently, it is in Phase II stage of clinical trial evaluation.
Interstitial Lung Disease Pipeline Therapeutics Assessment
There are approx. 120+ key companies which are developing the therapies Interstitial Lung Disease. The companies which have their Interstitial Lung Disease drug candidates in the most advanced stage, i.e phase III include Pfizer
Request a sample and discover the recent advances in Interstitial Lung Disease Ongoing Clinical Trial Analysis and Medications, click here @ Interstitial Lung Disease Treatment Landscape
Scope of the Interstitial Lung Disease Pipeline Report
Dive deep into rich insights for drugs for Interstitial Lung Disease Market Drivers and Interstitial Lung Disease Market Barriers, click here @ Interstitial Lung Disease Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Interstitial Lung Disease Mergers and acquisitions, Interstitial Lung Disease Licensing Activities @ Interstitial Lung Disease Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services